Skip to main content

Doximity, Inc. (DOCS) Stock Analysis

Recovery setup · Temp Headwind edge

SellModerate Confidence

Healthcare · Health Information Services

Sell if holding. Momentum 3.6/10 is below the 5.0 floor at $24.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Weak growth.

Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members including 80%+ of U.S. physicians. Revenue from pharmaceutical manufacturers and health systems paying for Marketing, Hiring, and Workflow Solutions grew 20% in fiscal... Read more

$24.16+40.8% A.UpsideScore 5.6/10#7 of 13 Health Information Services
Stop $22.45Target $34.00(analyst − 10%)A.R:R 2.8:1
Analyst target$37.77+56.3%22 analysts
$34.00our TP
$24.16price
$37.77mean
$55

Sell if holding. Momentum 3.6/10 is below the 5.0 floor at $24.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Weak growth. Chart setup: Death cross but MACD improving, RSI 69. Score 5.6/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Attractive valuation
Risks
Leverage penalty (D/E 1.1): -0.5
Weak growth
Negative momentum

Key Metrics

P/E (TTM)20.3
P/E (Fwd)14.9
Mkt Cap$4.6B
EV/EBITDA15.3
Profit Mgn37.5%
ROE23.8%
Rev Growth9.8%
Beta1.42
DividendNone
Rating analysts30

Quality Signals

Piotroski F7/9

Options Flow

P/C0.28bullish
IV126%elevated
Max Pain$13-48.3% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerpharmaceutical manufacturer customers
    10-K Item 1A: 'We do not typically enter into long-term contracts with our pharmaceutical manufacturer customers, who represent a significant portion of our revenue'

Material Events(8-K, last 90d)

  • 2026-04-17Item 5.02HIGH
    CFO Anna Bryson resignation accepted April 13, 2026 (had been on medical leave since February 3, 2026). Siddharth Sitaram continues as interim CFO. Company conducting search; no permanent successor named.
    SEC filing →
  • 2026-02-05Item 5.02HIGH
    CFO Anna Bryson placed on medical leave effective February 3, 2026. Siddharth Sitaram (Chief Accounting Officer) appointed interim principal financial officer. No permanent successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
5.0

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Support Resistance
3.0
Bollinger
3.4
Gap
6.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
3.1
Ma Position
4.0
Macd
10.0
Volume distribution (falling OBV)Below 200-MA, MA slope -9.9%/30d — confirmed downtrend
GatesMomentum 3.6<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 13d<=14d (soft)A.R:R 2.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
69 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $20.55Resistance $25.65

Price Targets

$22
$34
A.Upside+40.7%
A.R:R2.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Momentum score 3.6/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-13 (13d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DOCS stock a buy right now?

Sell if holding. Momentum 3.6/10 is below the 5.0 floor at $24.16 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.1): -0.5; Weak growth. Chart setup: Death cross but MACD improving, RSI 69. Prior stop was $22.45. Score 5.6/10, moderate confidence.

What is the DOCS stock price target?

Take-profit target: $34.00 (+40.8% upside). Prior stop was $22.45. Stop-loss: $22.45.

What are the risks of investing in DOCS?

Leverage penalty (D/E 1.1): -0.5; Weak growth; Negative momentum.

Is DOCS overvalued or undervalued?

Doximity, Inc. trades at a P/E of 20.3 (forward 14.9). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about DOCS?

30 analysts cover DOCS with a consensus score of 4.1/5. Average price target: $38.

What does Doximity, Inc. do?Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members...

Doximity is the leading digital platform for U.S. medical professionals with over 2 million registered members including 80%+ of U.S. physicians. Revenue from pharmaceutical manufacturers and health systems paying for Marketing, Hiring, and Workflow Solutions grew 20% in fiscal 2025. Network effects create a moat as member scale drives physician engagement and increases value to marketing customers.

Related stocks: WAY (Waystar Holding Corp.) · PRVA (Privia Health Group, Inc.) · VEEV (Veeva Systems Inc.) · HNGE (Hinge Health, Inc.) · HQY (HealthEquity, Inc.)